CSPIA
EBS icon

Cary Street Partners Investment Advisory’s Emergent Biosolutions EBS Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5
Closed -$17 – 929
2023
Q3 		$17 Buy
+5
New +$28 ﹤0.01% 1861

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cary Street Partners Investment Advisory's EBS Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 5 shares — an estimated $17 sold.

Cary Street Partners Investment Advisory first reported a position in EBS in Q3 2023 and held it in 1 quarter. The position peaked at $17 in Q3 2023. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 5 Emergent Biosolutions shares in Q4 2023, an estimated $17.
  • Cary Street Partners Investment Advisory first reported a position in Emergent Biosolutions in Q3 2023 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Emergent Biosolutions position peaked at $17 in Q3 2023.
  • 134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.